-transparent.png){kind=logo}
The serum levels of carbamazepine (CBZ) and its 10,11-epoxide metabolite (CBZ-E) were determined in seven subjects after a single dose of CBZ (400 mg) in the control state and during co-administration of erythromycin (500 mg three times daily for 10 days). Erythromycin treatment was associated with a decrease in CBZ clearance and a prolongation of CBZ half-life, while CBZ-E levels were markedly reduced. These data provide evidence that erythromycin inhibits the conversion of CBZ to its epoxide metabolite.
Related Publications
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
September 1990,
Therapeutic drug monitoring,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
March 1976,
Clinical pharmacology and therapeutics,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
March 1991,
Therapeutic drug monitoring,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
November 2006,
Analytical and bioanalytical chemistry,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
January 1990,
Epilepsia,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
August 1996,
Journal of chromatography. B, Biomedical applications,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
January 1989,
Pharmacological research,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
June 1983,
Archives of general psychiatry,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
January 1988,
Therapeutic drug monitoring,
N Barzaghi, and
G Gatti, and
F Crema, and
M Monteleone, and
C Amione, and
L Leone, and
E Perucca
January 1977,
Drug metabolism and disposition: the biological fate of chemicals,
